Microbot Receives Notice of Allowance for U.S. Patent Covering its TipCAT™ Technology Platform
“This Notice of Allowance represents a further execution of our overall strategy to create value by protecting our assets and expanding our global IP portfolio to differentiate our unique products and create barriers to entry,” said
The allowed patent application covers a self-propelled device for locomotion through a lumen, the device comprising a set of serially arranged inflatable chambers configured for sequential inflation from a single fluid source, wherein at least one chamber has characteristics selected to provide a non-monotonous relationship between the inflation pressure within the chamber and its inflated size.
Globally, Microbot now has 34 patents issued/allowed and 17 patent applications pending worldwide.
Microbot™, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on
The ViRobTM technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRobTM please visit http://www.microbotmedical.com/technology/virob/.
TipCATTM is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCATTM, visit http://www.microbotmedical.com/technology/tipcat/.
CardioSertTM technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal surgery. The CardioSertTM technology features unique steering and stiffness control capabilities, and it was originally developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as peripheral intervention, neurosurgery and urology. CardioSertTM was part of a technological incubator supported by the Israel Innovation Authorities (formerly known as the
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
Source: Microbot Medical